509 related articles for article (PubMed ID: 20547991)
1. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Karlan BY; Taniguchi T; Fountzilas E; Francoeur N; Levine DA; Cannistra SA
J Clin Oncol; 2010 Aug; 28(22):3555-61. PubMed ID: 20547991
[TBL] [Abstract][Full Text] [Related]
2. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
3. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
[TBL] [Abstract][Full Text] [Related]
4. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
[TBL] [Abstract][Full Text] [Related]
5. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB
J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085
[TBL] [Abstract][Full Text] [Related]
8. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
9. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
[TBL] [Abstract][Full Text] [Related]
10. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
Zhang M; Liu G; Xue F; Edwards R; Sood AK; Zhang W; Yang D
Gynecol Oncol; 2016 Apr; 141(1):57-64. PubMed ID: 27016230
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
12. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
13. Update on PARP1 inhibitors in ovarian cancer.
Sessa C
Ann Oncol; 2011 Dec; 22 Suppl 8():viii72-viii76. PubMed ID: 22180407
[TBL] [Abstract][Full Text] [Related]
14. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
15. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
[TBL] [Abstract][Full Text] [Related]
16. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
Steffensen KD; Adimi P; Jakobsen A
Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
Gadducci A; Guerrieri ME
Crit Rev Oncol Hematol; 2017 Jun; 114():153-165. PubMed ID: 28477743
[TBL] [Abstract][Full Text] [Related]
18. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer treatment in mutation carriers/BRCAness.
Lorusso D; Perotto S
Minerva Ginecol; 2016 Oct; 68(5):566-78. PubMed ID: 26785283
[TBL] [Abstract][Full Text] [Related]
20. Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations.
Ragupathy K; Ferguson M
J Obstet Gynaecol; 2011; 31(2):178-9. PubMed ID: 21281038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]